Capecitabine: guaranteed access in adjuvant treatment of breast cancer

Eur J Hosp Pharm. 2023 Dec 27;31(1):84-85. doi: 10.1136/ejhpharm-2022-003650.

Authors

Ana Isabel Cachafeiro Pin¹, Laura Villaverde Piñeiro², Cecilia Alejandra Saenz Fernández³, Ignacio Fernández Sobrado⁴

Affiliations

¹ Pharmacy, Hospital Da Mariña, Burela, Galicia, Spain ana.isabel.cachafeiro.pin@sergas.es.
² Pharmacy, Hospital Comarcal de Monforte, Monforte de Lemos, Spain.
³ Pharmacy, Hospital Da Mariña, Burela, Galicia, Spain.
⁴ Medical Oncology, University Hospital Lucus Augusti, Lugo, Spain.

No abstract available

Keywords: HEALTH SERVICES ADMINISTRATION; MEDICAL ONCOLOGY; PHARMACEUTICAL PREPARATIONS; PHARMACY SERVICE, HOSPITAL; Pharmacology.

Publication types

Letter

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Breast Neoplasms* / drug therapy
Capecitabine / therapeutic use
Female
Fluorouracil / therapeutic use
Humans

Substances

Capecitabine
Fluorouracil
Antimetabolites, Antineoplastic